- Home
- CORT vs ROIV Comparison
CORT vs ROIV Comparison
Compare CORT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- ROIV
- Stock Information
- Founded
- CORT 1998
- ROIV 2014
- Country
- CORT United States
- ROIV United Kingdom
- Employees
- CORT N/A
- ROIV N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CORT Health Care
- ROIV Health Care
- Exchange
- CORT Nasdaq
- ROIV Nasdaq
- Market Cap
- CORT 7.1B
- ROIV 8.4B
- IPO Year
- CORT N/A
- ROIV N/A
- Fundamental
- Price
- CORT $70.59
- ROIV $10.76
- Analyst Decision
- CORT Strong Buy
- ROIV Buy
- Analyst Count
- CORT 4
- ROIV 4
- Target Price
- CORT $142.00
- ROIV $17.50
- AVG Volume (30 Days)
- CORT 1.4M
- ROIV 5.9M
- Earning Date
- CORT 05-05-2025
- ROIV 05-29-2025
- Dividend Yield
- CORT N/A
- ROIV N/A
- EPS Growth
- CORT 8.36
- ROIV N/A
- EPS
- CORT 1.14
- ROIV N/A
- Revenue
- CORT $685,446,000.00
- ROIV $122,585,000.00
- Revenue This Year
- CORT $35.85
- ROIV N/A
- Revenue Next Year
- CORT $35.22
- ROIV N/A
- P/E Ratio
- CORT $61.82
- ROIV N/A
- Revenue Growth
- CORT 30.93
- ROIV 140.04
- 52 Week Low
- CORT $25.35
- ROIV $8.73
- 52 Week High
- CORT $117.33
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CORT 50.86
- ROIV 49.33
- Support Level
- CORT $69.33
- ROIV $10.58
- Resistance Level
- CORT $73.36
- ROIV $11.77
- Average True Range (ATR)
- CORT 3.66
- ROIV 0.34
- MACD
- CORT -0.20
- ROIV -0.05
- Stochastic Oscillator
- CORT 39.15
- ROIV 15.13
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.